Search

Now showing items 1-10 of 17

Pharmacy Benefit Management, Cost-Effectiveness Analysis and Drug Formulary Decisions

Grabowski, Henry G; Mullins, CD (Social Science & Medicine, 1997-08)

Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act

Grabowski, Henry G; Vernon, John M (1992-10)

IN 1984, Congress enacted a new law that greatly affected the economics of the pharmaceutical industry in the United States. It has been characterized as the most important legislation affecting competition in the pharmaceutical ...

The Role of Cost-Effectiveness Analysis in Managed Care Decisions

Grabowski, Henry G (Pharmacoeconomics, 1998)

R&d Costs, Innovative Output and Firm Size in the Pharmaceutical Industry

DiMasi, Joseph A; Grabowski, Henry G; Vernon, John M (International Journal of the Economics of Business, 1995-01-01)

This study examines the relationships between firm size, R&D costs and output in the pharmaceutical industry. Project-level data from a survey of 12 US-owned pharmaceutical firms on drug development costs, development phase ...

Innovation and International Competitiveness in Pharmaceuticals

Grabowski, Henry G (Evolving Technology and Market Structure: Studies in Schumpeterian Economics, 1990)

The Costs and Returns to Pharmaceutical Research and Development

Grabowski, Henry G (Revista Internazionale di Scienze sociali (International Social Studies Review), 1992-09)

Longer Patents for Increased Genetic Competition: The Waxman-Hatch Act After One Decade

Grabowski, Henry G (PharmacoEconomics, 1996)

A New Look at the Returns and Risks to Pharmaceutical R&D

Grabowski, Henry G; Vernon, John M (1990-07)

This study investigates the returns to R&D for 100 new drugs introduced into the United States during the decade of the 1970s. In contrast to prior studies, it incorporates several significant structural changes that have ...

Product Liability in Pharmaceuticals: Comments on Chapters Eight and Nine

Grabowski, Henry G (The Liability Maze: The Impact of Liability Law on Safety and Innovation, 1991)

With an ever-increasing number of liability lawsuits, are corporations electing to play it safe rather than risk the uncertainties accompanying innovation? In The Liability Maze experts address the issues surrounding safety ...

Economic Evaluation of Drug Treatment for Psychiatric Disorders: The New Clinical Trial Protocol

Bannerman, Heather A; Grabowski, Henry G; Mauskopf, Josephine; Weisler, Ricard H; Zarkin, Gary A (Psychopharmacology: the Fourth Generation of Progress, 1995)